| |
| | Dostinex Official FDA information, side effects and uses. |
 | | In the placebo-controlled study (placebo n=20; cabergoline n=168), Dostinex produced a dose-related decrease in serum prolactin levels with prolactin normalized after 4 weeks of treatment in 29%, 76%, 74% and 95% of the patients receiving 0.125, 0.5, 0.75, and 1.0 mg twice weekly respectively. |
 | | In the 8-week, double-blind period of the comparative trial with bromocriptine (cabergoline n=223; bromocriptine n=236 in the intent-to-treat analysis), prolactin was normalized in 77% of the patients treated with Dostinex at 0.5 mg twice weekly compared with 59% of those treated with bromocriptine at 2.5 mg twice daily. |
 | | Since cabergoline is extensively metabolized by the liver, caution should be used, and careful monitoring exercised, when administering Dostinex to patients with hepatic impairment. |
| www.drugs.com /pro/dostinex.html (3118 words) |
|